BioLineRx (BLRX) Gross Profit (2024 - 2025)
BioLineRx (BLRX) posted Gross Profit of $154000.0 for Q4 2025, down 55.1% on a QoQ basis from $343000.0 in Q3 2025, and down 97.28% year-over-year from $5.7 million in Q4 2024.
BioLineRx (BLRX) has 2 years of Gross Profit data on file, last reported at $154000.0 in Q4 2025.
- In Q4 2025, Gross Profit fell 97.28% year-over-year to $154000.0; the TTM figure through Dec 2025 stood at $950000.0 (down 95.17% YoY), while the FY2025 annual figure was $950000.0, down 95.17% from the prior year.
- Gross Profit declined to $154000.0 in Q4 2025, from $343000.0 in the prior quarter.
- Across five years, Gross Profit topped out at $5.7 million in Q4 2024 and bottomed at $154000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 343,000.00 |
| Sep 30, 2025 | 343,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 221,000.00 |
| Mar 31, 2025 | 221,000.00 |
| Dec 31, 2024 | 5.66 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.40 Mn |